By Mill Chart
Last update: Dec 20, 2024
Our stock screening tool has identified EXELIXIS INC (NASDAQ:EXEL) as an undervalued gem with strong fundamentals. NASDAQ:EXEL boasts decent financial health and profitability while maintaining an attractive price point. We'll break it down further.
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:EXEL has received a 8 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:EXEL, the assigned 8 is noteworthy for profitability:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:EXEL, the assigned 8 reflects its health status:
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:EXEL scores a 7 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of EXEL for a complete fundamental analysis.
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
43.03
+0.66 (+1.56%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.